Results 1 to 10 of about 77,746 (246)
Thrombotic Thrombocytopenic Purpura in Interferon Beta-1a-Treated Patient Diagnosed with Relapsing-Remitting Multiple Sclerosis: A Case Report [PDF]
Life, 2022 Background: Secondary thrombotic thrombocytopenic purpura (TTP) due to interferon beta-1a intramuscular (im) treatment is an uncommon adverse effect with only a few cases in multiple sclerosis patients reported worldwide.
Cristina-Florentina Plesa +6 more
doaj +2 more sources
Journal of Research in Medical Sciences, 2021 COVID-19 outbreak has become a global health concern due to challenges in treatment and high mortality rate; therefore, its therapeutic approaches play an important role in reducing the mortality rate and resolving this concern.
Rana Saleh +6 more
doaj +2 more sources
Manifestation of Susac syndrome during interferon beta-1a and glatiramer acetate treatment for misdiagnosed multiple sclerosis: a case report [PDF]
BMC Ophthalmology, 2021 Background Susac syndrome (SS) is characterized by the triad of encephalopathy, branch retinal artery occlusion, and sensorineural hearing loss. However, the diagnosis of SS remains difficult because the clinical triad rarely occurs at disease onset, and
Joanna Roskal-Wałek +5 more
doaj +2 more sources
Interferon beta-1a-induced morphea. [PDF]
JAAD Case Rep, 2015 Interferon beta-1a (IFN-β1a) is a cytokine therapy used in the treatment of relapsing-remitting multiple sclerosis. The most common adverse injection site reactions include local erythema, pain, and induration.1 Other less frequently encountered reactions include vascular thrombosis, ulceration, panniculitis, and lipoatrophy.1 More recently, IFN-β ...
Bezalel SA, Strober BE, Ferenczi K.
europepmc +4 more sources
Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis [PDF]
Arquivos de Neuro-Psiquiatria, 2002 Depression and suicide have been reported in association with multiple sclerosis (MS). Some studies show that interferon beta may increase the depression rate.
Marco Aurélio Lana-Peixoto +2 more
doaj +1 more source
Immunomodulatory treatment in multiple sclerosis: experience at a Brazilian center with 390 patients [PDF]
Arquivos de Neuro-Psiquiatria, 2006 Since 1993 the Federal Drug Administration approved the use of immunomodulatory therapy in multiple sclerosis (MS), modifying the natural course of disease, as demonstrate our experience in treatment of MS patients at the MS Treatment Center (CATEM ...
Charles Peter Tilbery +4 more
doaj +1 more source
BMC Neurology, 2019 Background Interferon (IFN) beta drugs have been approved for the treatment of relapsing forms of multiple sclerosis (RMS) for more than 20 years and are considered to offer a favourable benefit-risk profile. In July 2014, subcutaneous (SC) peginterferon
Annette Kolb-Mäurer +4 more
doaj +1 more source
Nowe perspektywy leczenia wtórnie postępującej postaci stwardnienia rozsianego
Aktualności Neurologiczne, 2015 Stwardnienie rozsiane jest przewlekłą autoimmunologiczną chorobą ośrodkowego układu nerwowego o nieznanej przyczynie i zmiennym przebiegu. W około 85% przypadków najpierw występuje postać rzutowo-remisyjna, która po pewnym czasie (różniącym się w ...
Magdalena Noga, Halina Bartosik-Psujek
doaj +1 more source
BMC Health Services Research, 2020 Background To differentiate five formulations of Interferon Beta for the treatment of multiple sclerosis (MS) in clinical practice, by analysing persistence, adherence, healthcare resource utilisation and costs at population level.
Marcello Moccia +7 more
doaj +1 more source
مجله دانشکده پزشکی اصفهان, 2018 Background: Treatment has a major effect on attacks in patients with multiple sclerosis (MS). This study aimed to determine the effect of the type of used drug on occurrence and number of attacks in patients with multiple sclerosis.
Marjan Jamalian +4 more
doaj +1 more source